1476206781_social-instagram-new-square2Mizhnarodny_Logotip_VK
Next generation investment company
Need help?Сontacts
Phone  +356 2015 0555 Call us 24/7

We use cookies on our website to provide you with a better user experience.

Top 7 Asian Stocks You Probably Haven’t Heard Of

We are wrapping up our spring series of reviews on top growing stocks listed on the world’s exchanges. Today we will talk about the stocks on Asia-Pacific markets that have seen the biggest increase in price over the past six months, from October 2017 to April 2018.

In order to make the list, a company needed to have a market cap of at least $10 billion and a decent P/E ratio, which ensures that each particular stock is fairly well known across relevant markets, while having little to no chances of suddenly being exposed as a bubble.

The readings on the charts below refer to the currencies used by the respective exchanges. The remaining data are in US dollars, and the $ symbol stands for the US dollar only.

The figures in the overview are based on data from the stock screener msn.com.

1. 360 Security Technology

360 Security Technology App screenshot

  • Symbol: 601360
  • Exchange: Shanghai Stock Exchange
  • Country: China
  • Currency: RMB
  • Market cap: $39B
  • Annual turnover: $345M
  • P/E ratio: 263
  • Dividend yield 0.4%
  • 6-month price change: +318%

Profile. A technology company principally engaged in the research and development of technology and products in the field of cybersecurity. Its other activities include research and development of intelligent wearable products, intelligent home systems, and internet services such as search engines and broadcasting platforms.

Chart. Since 2013, the company’s shares traded in the range of 6–20 yuan, showing a very unpronounced positive trend. It wasn’t until 2016 that the stock experienced a rally, soaring sixfold over the next year to reach an all-time high in early 2018. Later the stock lost about 25% of its value in an expected correction, but the current price is still quite high compared to that of before 2017.

Pros. Best share-price gain in the review, even when accounted for the recent correction .

Cons. Unreasonably high P/E ratio, probably indicating an upcoming correction; extremely low dividends.

2. Vingroup JSC

The Landmark 81 construction project

  • Symbol: VIC
  • Exchange: Ho Chi Minh City Stock Exchange
  • Country: Vietnam
  • Currency: VND
  • Market cap: $13B
  • Annual turnover: $1.5B
  • P/E ratio: 89
  • Dividend yield: 2.5%
  • 6-month price change: +88%

Profile. Originally founded in Ukraine in 1993 as a food-processing company, Vingroup is now the largest real estate conglomerate in Vietnam. Its founder, Pham Nhat Vuong, still owns about 30% of its shares, which makes him not only the company’s largest shareholder but also the richest man in Vietnam. Vingroup is primarily engaged in such areas as property development and management, hospitality and entertainment, and consumer retail. Vingroup operates 1,000 malls in Vietnam, while the company’s amusement parks get about 4 million visitors a year.

Chart. The stock has been on a clear positive price trend since 2013, but its first real rally started as recently as in 2017. In less than a year, the company’s share price has risen threefold, setting a new record in 2018. Unlike 360 Security, the company maintained a relatively reasonable P/E ratio, so the correction following the rally wasn’t at all painful.

Pros. Long-term share price uptrend, relatively high dividend payout.

Cons. High P/E ratio (still dramatically lower than that of 360 Security).

3. WuXi Biologics Cayman

Expert scientist in lab

  • Symbol: 2269
  • Exchange: Hong Kong Stock Exchange
  • Country: China
  • Currency: HKD
  • Market cap: $12B
  • Annual turnover: $446B
  • P/E ratio: 286
  • Dividend yield: –
  • 6-month price change: +70%

Profile. An investment holding company founded in 2010 and primary focused on the biotech sector. The Company develops and manufactures pharmaceutical ingredients, as well as provides research services in the field.

Chart. No data on the stock are available before 2Q 2017, but the general trend was clearly positive ever since, with the price having increased more than twice over the period. The stock reached an all-time high in 2018.

Pros. Great performance over the past six months.

Cons. Extremely high P/E ratio; no dividend payout.

4. FamilyMart UNY Holdings

FamilyMart store in Thailand

  • Symbol: 8028
  • Exchange: Tokyo Stock Exchange
  • Country: Jaраn
  • Currency: JPY
  • Market cap: $13B
  • Annual turnover: n/a
  • P/E ratio: 49
  • Dividend yield 1.2%
  • 6-month price change: +67%

Profile. One of the world’s largest convenience store franchise operators, founded in 1973 in Japan. At the moment, FamilyMart stores operate in Taiwan, China, Philippines, Vietnam, Thailand, South Korea, Indonesia and Malaysia. Out of 24,000 stores, more than 17,000 are located in Japan, outnumbered only by 7-Eleven outlets.

Chart. The stock exposes a positive price trend since 2013. After a brief dip in 2017, FamilyMart shares soared to the new records, doubling in price in just a year.

Pros. Rapid share price growth while maintaining a reasonable P/E ratio.

Cons. No significant disadvantages were found.

5. Aier Eye Hospital Group

Chinese Aier Eye Hospital

  • Symbol: 300015
  • Exchange: Shenzhen Stock Exchange
  • Country: China
  • Currency: RMB
  • Market cap: $12B
  • Annual turnover: $942M
  • P/E ratio: 89
  • Dividend yield 0.3%
  • 6-month price change: +62%

Profile. A nation-wide chain of professional ophthalmic medical institutions, founded in 2003 and headquartered in China. The company offers various types of eye disease diagnosis and treatment, including surgical services.

Chart. Over the past five years, Aier Eye stock behaved similarly to that of FamilyMart, establishing a weak positive trend that was seen until 2017, when after a brief dip the stock soared to new heights. Aier share price is currently six times higher than in 2013.

Pros. Long-term share price uptrend and an ongoing rally.

Cons. Relatively high P/E ratio, extremely low dividends.

6. Sino Biopharmaceutical

Medicinal drugs

  • Symbol: 1177
  • Exchange: Hong Kong Stock Exchange
  • Country: China
  • Currency: HKD
  • Market cap: $20B
  • Annual turnover: $2.3B
  • P/E ratio: 51
  • Dividend yield 0.4%
  • 6-month price change: +61%

Profile. An investment holding company engaged in the manufacturing and selling of pharmaceutical products, including ones based on the traditional Chinese medicine and intended to provide the treatment of such diseases as hepatitis, cerebral circulation diseases, oncology.

Chart. No pricing data on the stock are available from before 2011, but since then the general trend remains positive, and that’s putting it mildly, as the share price increased 87 times over the period. The most prominent rally, which started summer 2017, led to led to a three-fold increase in price alone.

Pros. Rapid share price growth while maintaining a reasonable P/E ratio.

Cons. Extremely low dividends.

7. Hengli Petrochemical

Oil-refining plant

  • Symbol: 600346
  • Exchange: Shanghai Stock Exchange
  • Country: China
  • Currency: RMB
  • Market cap: $13B
  • Annual turnover: $3.5B
  • P/E ratio: 25
  • Dividend yield: 1.0%
  • 6-month price change: +61%

Profile. Oil-refining and instrument-making company founded in 2002 in Dalian, China. The company’s main products include civilian polyester filaments, industrial polyester filaments, polyester chips and polyester films, and other plastic products, while its main sales markets are located in China, Europe, USA, Australia, Africa.

Chart. In case with this company, as with Sino Biopharmaceutical before, we use a broader chart scope to reveal the long-term price trend. You can see that the stock was actually losing its value until the trend reversal in 2005, and now its share price is 30 times higher. Like most of other stocks in the list, Hengli stock is currently traded around its latest high.

Pros. Great long-term share price growth, moderate P/E ratio.

Cons. No significant disadvantages were found.

All information is taken from the stock screener msn.com. The survey in this text is provided to you for informational and analytical purposes only and should not be regarded as an offer or solicitation of an offer to buy or sell any investments or related services that may be referenced here.

 

Read more

Created by professionals. For professionals.
Nearest representative office:  EXANTE LTD. (London Branch)
1 Fore Street,
London
EC2Y 9DT +44 2036709945